Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Dainippon Will Buy Boston Biomedical

by Michael McCoy
March 5, 2012 | A version of this story appeared in Volume 90, Issue 10

Dainippon Sumitomo Pharma has agreed to acquire Boston Biomedical Inc. for $200 million. Based in Norwood, Mass., BBI is developing two small-molecule drugs that work by targeting cancer stem cells. One, BBI608, is being prepared for a Phase III clinical trial as a colorectal cancer treatment and is in Phase Ib and II trials for various solid tumors. The other, BBI503, is in Phase I trials for solid tumors. Under the deal, BBI’s six shareholders also can get up to $540 million in developmental milestone payments. Dainippon Sumitomo licensed Japanese rights to BBI608 in March 2011.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.